D. Du and C. , 35 a. Dépistage génétique, 35 b. Résultats des principales études dans le dépistage des populations à risque familial de CaP ...... 35

I. Du and C. , 60 a. Diagnostic précoce de CaP dans, ., p.61
URL : https://hal.archives-ouvertes.fr/cea-01483788

G. Andriole, E. Crawford, R. Grubb, S. Buys, D. Chia et al., Mortality Results from a Randomized Prostate-Cancer Screening Trial, New England Journal of Medicine, vol.360, issue.13, p.13109, 2009.
DOI : 10.1056/NEJMoa0810696

]. Internet and . Globocan2102, Disponible sur http

. Le-cancer-de-la-prostate, évolution de l'incidence et de la mortalité en France entre, Prog Urol [Internet]. juill, vol.25, issue.9, p.53642, 1980.

G. Epidémiologie-du-cancer-de-la-prostate-draisma, R. Etzioni, A. Tsodikov, A. Mariotto, E. Wever et al., e-cancer.fr Disponible sur: http://lesdonnees.e-cancer.fr/Themes/epidemiologie 7 Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

M. Yin, S. Bastacky, U. Chandran, M. Becich, R. Dhir et al., Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors):892895; discussion 895. 10 Explaining racial differences in prostate cancer mortality. Cancer):42809. 11. Cancel-Tassin G, Cussenot O. Genetic susceptibility to prostate cancer, ):13805. 12. Tran HN Risk of cancer in Asian Americans: a Kaiser Permanente cohort study. Cancer Causes Control, p.25, 2005.

A. Olama, A. Kote-jarai, Z. Berndt, S. Conti, D. Schumacher et al., A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer, Nature Genetics, vol.321, issue.10
DOI : 10.1158/1078-0432.CCR-07-2051

A. Valeri, G. Fournier, V. Morin, J. Morin, E. Drelon et al., Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives Hereditary prostate cancer: epidemiologic and clinical features, Int J Cancer. 15 juin J Urol. sept, vol.86150, issue.63, p.797802, 1993.

L. E. Johns, R. Houlston, U. Kristoffersson, R. Lundgren, and H. Olsson, A systematic review and meta-analysis of familial prostate cancer risk Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study Family history and prostate cancer risk, BJU Int [Internet]. 1 juin Eur J Cancer. févr Lesko SM Am J, vol.9135, issue.92, pp.2727-2745, 1999.

E. Hayes, R. Liff, J. Pottern, L. Greenberg, R. Schoenberg et al., 1 déc, p.10417, 1996.

K. Hemminki and K. Czene, Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer. 15 sept, p.134653, 2002.

G. Steinberg, B. Carter, T. Beaty, B. Childs, and P. Walsh, Family history and the risk of prostate cancer, The Prostate, vol.60, issue.4, p.33747, 1990.
DOI : 10.1002/pros.2990170409

S. Little, Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease, Br J Cancer, vol.110, issue.6, p.166372, 2014.

B. Carter, T. Beaty, G. Steinberg, B. Childs, and P. Walsh, Evidence of an X-linked or recessive genetic component to prostate cancer risk Mendelian inheritance of familial prostate cancer, Nat Med. août Proc Natl Acad Sci, vol.189, issue.258, p.8279336771, 1992.

X. Gao, M. Lavalley, and K. Tucker, Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis, J Natl Cancer Inst, vol.97, issue.23, p.176877, 2005.

R. Ma and K. Chapman, A systematic review of the effect of diet in prostate cancer prevention and treatment, Journal of Human Nutrition and Dietetics, vol.98, issue.Suppl. 4, pp.187-199, 2009.
DOI : 10.1113/expphysiol.1997.sp004024

E. Jacobs, L. Kohler, A. Kunihiro, and P. Jurutka, Vitamin D and Colorectal, Breast, and Prostate Cancers: A Review of the Epidemiological Evidence, Journal of Cancer, vol.7, issue.3, p.23240, 2016.
DOI : 10.7150/jca.13403

Y. Wang, E. Jacobs, C. Newton, M. Mccullough, P. Nelson et al., Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II Nutrition Cohort Unconventional therapy for prostate cancer: good, bad or questionable? Etminan M, Takkouche B, Caamaño-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies, Int J Cancer. 15 juin Nat Rev Cancer. nov, vol.1383, issue.32, pp.284655-3184558, 2003.

R. Martí, S. Roselló, and J. Cebolla-cornejo, Tomato as a Source of Carotenoids and Polyphenols Targeted to Cancer Prevention, Cancers, vol.18, issue.6, pp.3405-3438, 2004.
DOI : 10.1016/j.scienta.2014.06.010

N. Kurahashi, S. Sasazuki, M. Iwasaki, M. Inoue, S. Tsugane et al., Green Tea Consumption and Prostate Cancer Risk in Japanese Men: A Prospective Study, American Journal of Epidemiology, vol.167, issue.1, p.717, 2008.
DOI : 10.1093/aje/kwm249

S. Bettuzzi, M. Brausi, F. Rizzi, G. Castagnetti, G. Peracchia et al., Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study, Cancer Research, vol.66, issue.2, p.123440, 2006.
DOI : 10.1158/0008-5472.CAN-05-1145

N. Allen, R. Travis, P. Appleby, D. Albanes, M. Barnett et al., Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies, Journal of the National Cancer Institute, vol.12, issue.9, 2016.
DOI : 10.1007/s00394-009-0023-0

URL : https://hal.archives-ouvertes.fr/hal-01607635

M. Paltsev, V. Kiselev, V. Drukh, E. Muyzhnek, I. Kuznetsov et al., First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIMbased therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN), The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, p.122842, 2005.

J. Epstein, L. Egevad, M. Amin, B. Delahunt, J. Srigley et al., The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, The American Journal of Surgical Pathology, vol.40, issue.2, p.24452, 2016.
DOI : 10.1097/PAS.0000000000000530

J. Epstein, A. Amico, R. Whittington, S. Malkowicz, D. Schultz et al., Gleason Score 2???4 Adenocarcinoma of the Prostate on Needle Biopsy, The American Journal of Surgical Pathology, vol.24, issue.4, pp.4778-4196974, 1998.
DOI : 10.1097/00000478-200004000-00001

J. Epstein, P. Walsh, M. Carmichael, and C. Brendler, Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer, ESTRO-SIOG Guidelines on Prostate Cancer, pp.36874-36918, 1994.

J. Natl-cancer-inst, H. Seo, N. Lee, S. Son, D. Kim et al., Comparison of Robot-Assisted Radical Prostatectomy and Open Radical Prostatectomy Outcomes: A Systematic Review and Meta-Analysis):116577. 46. assisted radical prostatectomy compared with open and laparoscopic approaches: a systematic review and meta-analysis Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy, Yonsei Med J. sept Int J Urol. mars J Urol. avr Eur Urol, vol.995720181, issue.482, pp.14849-45181722, 2007.

F. Greco, M. Hoda, S. Wagner, O. Reichelt, A. Inferrera et al., Bilateral vs unilateral laparoscopic intrafascial nerve-sparing radical prostatectomy: evaluation of surgical and functional outcomes in 457 patients, BJU International, vol.55, issue.4, p.5837, 2011.
DOI : 10.1016/j.eururo.2008.09.051

V. Ficarra, G. Novara, R. Rosen, W. Artibani, P. Carroll et al., Systematic Review and Meta-analysis of Studies Reporting Urinary Continence Recovery After Robotassisted Radical Prostatectomy, Eur Urol [Internet]. sept, vol.62, issue.3, p.40517, 2012.

T. Yu, Q. Zhang, T. Zheng, H. Shi, Y. Liu et al., The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures, PLOS ONE, vol.58, issue.5, p.154499, 2016.
DOI : 10.1371/journal.pone.0154499.s002

L. Klotz, A. Taira, G. Merrick, R. Galbreath, K. Wallner et al., Active surveillance and focal therapy for low-intermediate risk prostate cancer Natural history of clinically staged low-and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy, Transl Androl Urol. juin Int J Radiat Oncol Biol Phys. 1 févr, vol.476, issue.32, pp.34254-5434954, 2010.

W. Yan, J. Chen, Y. Zhou, Z. Zhou, Z. Mai et al., Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years, SpringerPlus, vol.3, issue.1
DOI : 10.1186/2193-1801-3-357

. Med, 14 juill, p.10718, 2011.

N. Munro, B. Al-qaisieh, P. Bownes, J. Smith, C. B. Bottomley et al., Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125
DOI : 10.1016/j.radonc.2010.03.004

C. Tangen, J. Paradelo, M. Lucia, G. Miller, and D. Troyer, Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial, monotherapy over 10 years, p.347, 2010.

I. Thompson, C. Tangen, J. Paradelo, M. Lucia, G. Miller et al., Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial, The Journal of Urology, vol.181, issue.3, pp.232935-6495662, 2006.
DOI : 10.1016/j.juro.2008.11.032

A. Valeri, Epidemiology of familial prostatic cancer: 4-year assessment of French studies] Heterogeneity in genetic susceptibility to prostate cancer, Prog Urol. sept Eur J, vol.9, issue.68, 1999.

L. Kerr, M. Rewhorn, M. Longmuir, S. Fraser, S. Walsh et al., A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer, BMC Cancer, vol.13, issue.1
DOI : 10.1007/s10689-014-9744-1

C. Ewing, A. Ray, and E. Lange, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, vol.31, issue.14, pp.174857-72, 2013.

Z. Kote-jarai, D. Leongamornlert, E. Saunders, M. Tymrakiewicz, E. Castro et al., BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, British Journal of Cancer, vol.91, issue.8, p.12304, 2011.
DOI : 10.1158/1078-0432.CCR-07-5237

G. Andriole, E. Crawford, R. Grubb, S. Buys, D. Chia et al., Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up Prostate Cancer Mortality Reduction by Prostate-Specific Antigen?Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC), J Natl Cancer Inst Roobol MJ Eur Urol [Internet]. oct, vol.104, issue.564, pp.12532-7558491, 2009.

M. Peyromaure, P. Beuzeboc, L. Salomon, P. Richaud, P. Coloby et al., Le d??pistage du cancer de la prostate en 2009??: mise au point du comit?? de canc??rologie de l???Association fran??aise d???urologie, ):1723. 77. Schröder FH, 2010.
DOI : 10.1016/j.purol.2009.09.033

M. Matikainen, J. Schleutker, P. Mörsky, O. Kallioniemi, T. Tammela et al., Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from highrisk prostate cancer families):12759. 80. Standaert B, Denis L. The European Randomized Study of Screening for Prostate Cancer: an update Screening for prostate cancer in high risk populations, Clin Cancer Res. juin Cancer. 1 nov J Urol. nov, vol.580168, issue.815, pp.183041980-1983, 1997.

M. Liss, H. Chen, S. Hemal, S. Krane, C. Kane et al., Impact of Family History on Prostate Cancer Mortality in White Men Undergoing Prostate Specific Antigen Based Screening, The Journal of Urology, vol.193, issue.1
DOI : 10.1016/j.juro.2014.07.085

. Urol, M. Janv, A. Müller, S. Carlsson, D. Eberli et al., A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer, BJU Int. avr, vol.193117, issue.14, pp.759-8357683, 2015.

E. Bancroft, E. Page, E. Castro, H. Lilja, A. Vickers et al., Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study):48999. 85. Cussenot O, Cancel-Tassin G. Le point sur la prédisposition génétique pour le cancer de la prostate, Eur Urol. sept Bull Cancer [Internet]. janv, vol.66102, issue.31, p.536, 2014.

E. Negri, C. Pelucchi, R. Talamini, M. Montella, S. Gallus et al., Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia, International Journal of Cancer, vol.159, issue.4, p.64852, 2005.
DOI : 10.1093/oxfordjournals.epirev.a000795

M. Kwiatkowski, A. Huber, B. Stamm, K. Lehmann, and R. Tscholl, Family history in the Finnish Prostate Cancer Screening Trial Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3, Int J Cancer. 1 mai, vol.136, issue.9, 2015.

A. Valeri, P. Berthon, G. Fournier, J. Buzzi, L. Briollais et al., combined with free-to-total ratio 20% or less: the Aarau experienceThe PROGENE study, the French project of genetic analysis of familial prostatic cancer: recruitment and analysis] Generalized linear mixed models: a review and some extensions, ):22635. 90. Dean CB, pp.8515-89497512, 1996.

Y. Kanda, Statistical analysis using freely-available « EZR (Easy R) » software

R. Azzouzi, E. Drelon, A. Delannoy, P. Mangin, and G. Fournier, Pathological findings after radical prostatectomy in men eligible for active surveillance (French trial SURACAP): is the misclassification rate acceptable?] Early-onset hereditary prostate cancer is not associated with specific clinical and biological features, Prog Urol. avr, vol.21, issue.4, 2011.

D. Goldgar, D. Easton, L. Cannon-albright, and M. Skolnick, Systematic populationbased assessment of cancer risk in first-degree relatives of cancer probands, J Natl Cancer Inst nov, vol.86, issue.221, p.16008, 1994.

P. Ghadirian, G. Howe, T. Hislop, P. Maisonneuve, C. Selkirk et al., Family history of prostate cancer: a multi-center case-control study in Canada Family history of prostate cancer in men being followed by active surveillance does not increase risk of being diagnosed with high-grade disease, Int J Cancer. 17 mars Urology. avr, vol.7085, issue.64, pp.67981-967427, 1997.

E. Crawford, J. Moul, K. Rove, C. Pettaway, L. Lamerato et al., Prostatespecific antigen 1.5?4.0 ng/mL: a diagnostic challenge and danger zone, BJU Int, issue.1

M. Randazzo, J. Beatrice, A. Huber, R. Grobholz, L. Manka et al., Is further screening of men with baseline PSA < 1 ng ml(-1) worthwhile? The discussion continues- Results of the Swiss ERSPC (Aarau), déc Int J Cancer. 1 août, vol.108137, issue.113, pp.17439-985539, 2011.